N/A
N=20
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
Anterior Wall Acute Myocardial Infarction
Bottom Line
View on ClinicalTrials.gov: NCT01630707 ↗Enrolled (actual)
20
Serious AEs
10.0%
Results posted
May 2026
Primary outcome: Primary: The Feasibility of Intracoronary Infusion of SSO2 Therapy — 20 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- SuperSaturated Oxygen (SS02) Therapy (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- TherOx
- Primary completion
- Sep 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Feasibility of Intracoronary Infusion of SSO2 Therapy |
20 | — |
| SECONDARY Median Myocardial Salvage Index |
49.9 | — |
| SECONDARY Median Infarct Size by Cardiac MRI |
9.6 | — |
| SECONDARY Median Infarct Size by Cardiac MRI |
9.6 | — |
| SECONDARY MACE - CEC Adjudicated |
1 | — |
| SECONDARY Target Vessel Failure (TVF) - CEC Adjudicated |
1 | — |
| SECONDARY Cardiac Death - CEC Adjudicated |
— | — |
| SECONDARY Vascular Death - CEC Adjudicated |
— | — |
| SECONDARY Non-Cardiovascular Death |
— | — |
| SECONDARY New-Onset Heart Failure - CEC Adjudicated |
1 | — |
| SECONDARY Heart Failure Requiring Hospitalization - CEC Adjudicated |
— | — |
| SECONDARY Re-Hospitalization for Previous Heart Failure - CEC Adjudicated |
— | — |
| SECONDARY Myocardial Infarction - CEC Adjudicated |
1 | — |
| SECONDARY Myocardial Infarction, Spontaneous - CEC Adjudicated |
— | — |
| SECONDARY Myocardial Infarction, Periprocedural (PCI) - CEC Adjudicated |
— | — |
| SECONDARY Myocardial Infarction, Periprocedural (CABG) - CEC Adjudicated |
— | — |
| SECONDARY Myocardial Infarction, STEMI - CEC Adjudicated |
1 | — |
| SECONDARY Myocardial Infarction, NSTEMI - CEC Adjudicated |
— | — |
| SECONDARY Repeat Angiography/Revascularization - CEC Adjudicated |
1 | — |
| SECONDARY Clinically Driven Target Lesion Revascularization (TLR) - CEC Adjudicated |
1 | — |
| SECONDARY Clinically Driven Target Vessel Revascularization (TVR) - CEC Adjudicated |
1 | — |
| SECONDARY Stent Thrombosis (ARC Criteria) - CEC Adjudicated |
1 | — |
| SECONDARY Definite Stent Thrombosis (ARC Criteria) - CEC Adjudicated |
1 | — |
| SECONDARY Probable Stent Thrombosis (ARC Criteria) - CEC Adjudicated |
— | — |
| SECONDARY Possible Stent Thrombosis (ARC Criteria) - CEC Adjudicated |
— | — |
| SECONDARY Neurologic Event (Stroke, TIA) - CEC Adjudicated |
— | — |
| SECONDARY Hemorrhagic/Vascular Event - CEC Adjudicated |
1 | — |
Summary
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA). The therapy will be delivered with a commercially available qualified SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the treatment of patients presenting with an anterior acute myocardial infarction (heart attack) ≤ six hours after symptom onset with successful reperfusion (via PCI).
Eligibility Criteria
GENERAL INCLUSION CRITERIA: Candidates for this study must meet ALL of the following criteria:
Pre-PCI:
- The subject must be ≥18 and ≤80 years of age.
- AMI must be anterior.
- Subject is experiencing clinical symptoms consistent with anterior AMI of ≤6 hour duration.
- Signed Informed Consent.
- Subject agrees to all required follow-up procedures and visits.
- Negative pregnancy test for women of childbearing potential.
ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to enrollment:
- PCI is indicated for revascularization of the culprit lesion(s) with use of a commercially available coronary stent in the LAD.
- The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD coronary artery.
- Baseline (pre-PCI) TIMI flow grade 0, 1, 2, or 3 flow in the LAD.
- Successful angioplasty and no major complications such as perforation or shock.
- Expected ability to place the SSO2 delivery catheter in the coronary ostium of the left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.
- Planned revascularization of a non-target lesion is allowed.
Patients will be excluded if ANY of the following conditions apply:
GENERAL EXCLUSION CRITERIA
Pre-PCI:
- Prior CABG surgery.
- Prior myocardial infarction, or known prior systolic dysfunction.
- Thrombolytic therapy administered for this STEMI.
- An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first 30 days post-enrollment.
- Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the anterior AMI.
- Subjects who have previously undergone angioplasty or stenting in the LAD.
- Subjects with ventricular pseudoaneurysm, VSD, or severe mitral valve regurgitation.
- Any contraindication to undergo MRI imaging.
- Impaired renal function or on dialysis.
- Known platelet count 700, 000 cells/mm3 or a known Hgb 20%.
- Any untreated LAD or diagonal branch lesion is present with diameter stenosis >= 50% in a vessel with reference vessel diameter > 2.0 mm or for which PCI will be required before the MRI study.
- Presence of a non-stented coronary dissection upon completion of the PCI procedure.
Data sourced from ClinicalTrials.gov (NCT01630707). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.